Table 8. Likelihood of receipt of chemotherapy by SEP group (non-universal health care systems).
| Study | No. Receiving Chemo | Cohort No./No. Eligible | Rate | Stage | Histology | OR/Rate in Q1 (95% CI) | OR/Rate in Q2 (95% CI) | OR/Rate in Q3 (95% CI) | OR/Rate in Q4 (95% CI) | OR/Rate in Q5 (95% CI) | p-Value | Quality Score | Meta-Analysis | Further Information |
| Bradley et al, 2008 [57] | 643 | 2348 | 27.39 | I,II, IIIa | NSCLC | 1.00 | 1.09 (0.87 to 1.37) | >0.05 | 4 | Y | ||||
| Hardy et al, 2009 [62] | 2951 | 19658 | 15.01 | I, II | NSCLC | 1.00 | 0.91 (0.81 to 1.02) | 0.96 (0.85 to 1.09) | 0.85 (0.74 to 0.98) | >0.05, >0.05, <0.05 | 5 | Y | Individual p-values reported | |
| Ou et al, 2008 [70] | 1175 | 19700 | 5.96 | I | NSCLC | 5.3 | 5.7 | 5.3 | 6.9 | 7.4 | 0.001 | 2 | N | Univariable analysis |
| Davidoff et al, 2010 [58] | 5499 | 21285 | 25.84 | IIIB, IV | NSCLC | 1.43 (1.28 to 1.60) | 1.17 (1.05 to 1.30) | 1.11 (1.00 to 1.22) | 1.00 | <0.01, <0.01, <0.05 | 5 | Y | Individual p-values reported | |
| Earle et al, 2000 [59] | 1356 | 6308 | 21.50 | IV | NSCLC | 1.07 (1.02 to 1.12) | 0.0077 | 5 | N | Subset of Earle (2002) | ||||
| Earle et al, 2002 [68] | 8813 | 12015 | 73.35 | IV | NSCLC | 41 | 41 | 36 | 31 | 27 | >0.05 | 2 | N | Univariable analysis only. SEP was included in multivariable analysis but non-sig (figs not reported) |
| Hardy et al, 2009 [62] | 26417 | 51243 | 51.55 | III, IV | NSCLC | 1.00 | 0.87 (0.78 to 0.96) | 0.76 (0.63 to 0.90) | 0.60 (0.45 to 0.79) | <0.05, <0.05, <0.05 | 5 | Y(S) | Individual p-values reported | |
| Tammemagi et al, 2004 [72] | NR | 1155 | III,IV | NSCLC | 1.09 (1.01 to 1.18) | 0.03 | 2 | N | Univariable OR | |||||
| Davidoff et al, 2010 [58] | 749 | 1946 | 38.49 | IIIB, IV | NSCLC | 0.86(0.69 to 1.08) | 0.96 (0.77 to 1.19) | 0.99 (0.81 to 1.22) | 1.00 | NR | 5 | N | Odds of single agent compared to two-agent chemo. | |
| Wang et al, 2008 [73] | 1521 | 3196 | 47.59 | II, IIIa | NSCLC | 1.00 | 1.08 (0.97 to 1.21) | 1.08 (0.97 to 1.21) | 0.97 (0.85 to 1.10) | NR | 1 | N | Odds of receiving oncology consultation. | |
| Yang et al, 2010 [74] | NR | NR | All | any | 32.2 | 30.7 | 29.9 | 30.1 | <0.01 | 2 | N | Univariable analysis |
Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in Tables 1–4 in the column entitled “No. of SEP groups.” Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.
CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position.